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A study of novel bilateral thermal capsulotomy with 
focused ultrasound for treatment-refractory obsessive–
compulsive disorder: 2-year follow-up
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Won Seok Chang, MD, PhD; Chan-Hyung Kim, MD, PhD; Jin Woo Chang, MD, PhD
Introduction
Obsessive–compulsive disorder (OCD) tends to run a chronic 
course and cause severe distress. Patients with OCD usually 
show impaired social, academic and occupational function-
ing.1 The standard initial treatment for OCD consists of cog-
nitive behavioural therapy and pharmacotherapy with  sero-
tonin reuptake inhibitors. However, many people with OCD 
do not respond adequately to standard treatment2 and some 
fail to respond, even after all of the best available treatments 
have been attempted. For people with treatment-refractory 
OCD, an alternative approach using neurosurgical interven-
tions — including deep brain stimulation and ablative neuro-
surgery — has been applied with varying outcomes.3 
Recently, a new thermal lesioning approach using magnetic 
resonance–guided focused ultrasound (MRgFUS) has been in-
troduced for the treatment of neurologic disorders.4 Compared 
to other neurosurgical approaches, MRgFUS is a minimally 
invasive procedure involving non–cranium opening surgery, 
and it has no adverse radiation effects. In addition, closed-loop 
monitoring in real time allows for confirmation of lesion size 
and location during every stage of lesioning, as well as accu-
rate thermocoagulation.5 We previously described a proof-of-
concept study of bilateral thermal lesioning of the anterior 
limb of the internal capsule (ALIC) using MRgFUS in 4 pa-
tients with treatment-refractory OCD and following patients 
for 6 months.6 Here, we report the 2-year follow-up results for 
11 patients with treatment-refractory OCD (including the 
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Background: Recently, a new thermal lesioning approach using magnetic resonance–guided focused ultrasound (MRgFUS) was intro-
duced for the treatment of neurologic disorders. However, only 2 studies have used this approach for treatment-refractory obsessive–
compulsive disorder (OCD), and follow-up was short-term. We investigated the efficacy and safety of bilateral thermal lesioning of the 
anterior limb of the internal capsule using MRgFUS in patients with treatment-refractory OCD and followed them for 
2 years. Methods: Eleven patients with treatment-refractory OCD were included in the study. Clinical outcomes were evaluated using 
the Yale–Brown Obsessive Compulsive Scale, the Clinical Global Impression scale (including improvement and severity), the Hamil-
ton Rating Scale for Depression (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A) at 1 week and 1, 3, 6, 12 and 
24 months following MRgFUS. Neuropsychological functioning, Global Assessment of Functioning and adverse events were also as-
sessed. Results: After MRgFUS, Yale–Brown Obsessive Compulsive Scale scores decreased significantly across the 24-month 
follow- up period (mean ± standard deviation, 34.4 ± 2.3 at baseline v. 21.3 ± 6.2 at 24 months, p < 0.001). Scores on the Hamilton 
rating scales for depression and anxiety also significantly decreased from baseline to 24 months (HAM-D, 19.0 ± 5.3 v. 7.6 ± 5.3, p < 
0.001; HAM-A, 22.4 ± 5.9 v. 7.9 ± 3.9, p < 0.001). Global Assessment of Functioning scores improved significantly (35.8 ± 4.9 at 
baseline v. 56.0 ± 10.3 at 24 months, p < 0.001) and Memory Quotient significantly improved, but other neuropsychological functions 
were unchanged. The side effects of MRgFUS included headache and vestibular symptoms, but these were mild and transient. 
 Limitations: The main limitations of this study were the small sample size and the open-label design. Conclusion: Bilateral thermal 
lesioning of the anterior limb of the internal capsule using MRgFUS may improve obsessive–compulsive, depressive and anxiety 
symptoms in patients with treatment-refractory OCD, without serious adverse effects.
Kim et al.
328 J Psychiatry Neurosci 2018;43(5)
4 described in our previous report), who underwent bilateral 
thermal capsulotomy using MRgFUS. We evaluated efficacy in 
terms of the severity of obsessive–compulsive, depressive and 
anxiety symptoms, and we assessed whether MRgFUS caused 
any physical or cognitive adverse effects.
Methods
Participants
All 11 patients had treatment-refractory OCD and were re-
cruited from a patient pool at Severance Hospital, Yonsei Uni-
versity Health System, a tertiary hospital in South Korea. The 
inclusion criteria were as follows: a primary diagnosis of OCD 
according to the Structured Clinical Interview for DSM-IV7; 
at least a 3-year history of OCD symptoms with psychosocial 
dysfunction (determined by a Global Assessment of Function-
ing [GAF] score of ≤ 50)8; a minimum score of 28 on the 
Yale–Brown Obsessive Compulsive Scale (Y-BOCS)9; and 
treatment- refractory status — that is, nonresponsive to phar-
macological treatment (more than 2 types of serotonin reup-
take inhibitor at the maximum tolerated dose for more than 
12 weeks) and cognitive behavioural therapy (a minimum of 
20 sessions of primarily therapist-guided Exposure and 
Response Prevention [ERP]). Full inclusion and exclusion cri-
teria can be found at www.clinicaltrials.gov/ct2/show/NCT0
1986296?term=OCD001&rank=2. 
We initially recruited participants with more refractory 
characteristics than described in the inclusion criteria; the 
number of characteristics and duration of treatment exceeded 
the entry criteria for all patients. All patients had failed to re-
spond to more than 3 serotonin reuptake inhibitors, includ-
ing clomipramine, and more than 1 antipsychotic drug aug-
mentation strategy (≥ 3 serotonin reuptake inhibitors and ≥ 1 
antipsychotic) and had had symptoms of OCD with psycho-
social impairment for at least 5 years. Patients who had a cur-
rent or previous psychotic disorder, bipolar disorder or sig-
nificant cognitive impairment (based on a Mini Mental State 
Examination,10 score ≤ 24) were excluded from the study. All 
patients continued to take their previous medication, using 
the same regimen and the same dosage, over the entire 2-year 
study period. After the first week following MRgFUS, pa-
tients were encouraged to continue using the cognitive be-
havioural skills they had learned previously; we did not de-
liver regular, formal cognitive behavioural therapy sessions 
after the surgery. The CONSORT flow chart can be found in 
Appendix 1, Figure S1, available at jpn.ca/170188-a1.
This study was approved by the Institutional Review 
Board of Severance Hospital. All participants gave written in-
formed consent. This trial is registered with ClinicalTrials.
gov, number NCT01986296 (www.clinicaltrials.gov/ct2/
show/NCT01986296?term=OCD001&rank=2).
Outcomes
We measured the severity of obsessive–compulsive symp-
toms using the Y-BOCS.9 We also assessed Clinical Global 
Impression (CGI) scores, including improvement (CGI-I) and 
severity (CGI-S). Patients were classified as responders, par-
tial responders or nonresponders based on the criteria for 
treatment response and remission of obsessive–compulsive 
symptoms listed in Table 1.11 We assessed depressive and 
anxiety symptoms using the 17-item Hamilton Rating Scale 
for Depression (HAM-D)12 and the Hamilton Rating Scale for 
Anxiety (HAM-A),13 respectively. The criteria for treatment 
response and remission of depressive and anxiety symp-
toms14 are also listed in Table 1. We assessed Y-BOCS, CGI, 
HAM-D and HAM-A at baseline, 1 week, and 1, 3, 6, 12 and 
24 months. 
We conducted comprehensive neuropsychological tests at 
baseline and 6, 12 and 24 months, including the Korean ver-
sion of the Wechsler Adult Intelligence Scale (K-WAIS, intel-
lectual function),15 the Memory Quotients (visual and verbal 
memory ability) of the Rey-Kim Memory Test,16 the Con-
trolled Oral Word Association Test (COWAT, executive func-
tion),17 the Korean Colour Word Stroop Test (Stroop, execu-
tive function)18 and the Digit Span test (forward, attention).19
We assessed global psychosocial and occupational func-
tioning using the GAF8 test at baseline and 3, 6, 12 and 
24 months.
Adverse events or changes in a patient’s physical and 
 behavioural condition were evaluated during the surgical 
Table 1: Classification of treatment response for obsessive–compulsive, depressive and anxiety symptoms
Treatment response Definition
Obsessive-compulsive
Responder Y-BOCS reduction ≥ 35% relative to the baseline score + CGI-I 1 (very much improved) or 2 (much improved)
Partial responder Y-BOCS reduction 25%–35% + CGI-I ≥ 3 (minimally improved)
Remission Y-BOCS ≤ 12 + CGI-S 1 (normal, not at all ill) or 2 (borderline mentally ill) ≥ 1 week
Depressive
Responder HAM-A reduction ≥ 50% relative to the baseline score
Remission HAM-A ≤ 7
Anxiety
Responder HAM-D reduction ≥ 50% relative to the baseline score
Remission HAM-D ≤ 7
CGI-I = Clinical Global Impression–Improvement; CGI-S = Clinical Global Impression–Severity; HAM-A = Hamilton Rating Scale for Anxiety; HAM-D = Hamilton Rating Scale 
for Depression; Y-BOCS = Yale–Brown Obsessive Compulsive Scale.
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 procedure and at each follow-up visit by both an experienced 
neurosurgeon and psychiatrist, who questioned in general 
terms. Physical adverse events were also assessed using a 
physical examination checklist, and psychiatric adverse 
events were evaluated using mental status examinations and 
psychiatric interviews. All changes in physical and behav-
ioural condition reported by patients and caregivers were 
considered to be adverse events. 
Primary outcome measures were Y-BOCS and CGI. Sec-
ondary outcome measures were depression and anxiety 
symptoms (HAM-D, HAM-A), neuropsychological tests, 
global functioning (GAF) and adverse events associated with 
the procedure.
Focused ultrasound capsulotomy
The details of the focused ultrasound capsulotomy procedure 
have been decribed previously.6 In brief, MRgFUS sonica-
tions were performed using a 3-T MR (GE Medical Systems) 
and the ExAblate 4000 (InSightec) systems. The bilateral 
ALIC was targeted along the bicommisural line, 7 mm in 
front of the anterior margin of the anterior commissure. With 
stepwise increases in acoustic power and energy, high-power 
sonications were applied to achieve a peak temperature of 
51°C to 56°C for more than 3 s. The goal was to create a 
10 mm elliptical lesion along the internal capsule on coronal 
imaging by adjusting the target centre. Before and after every 
sonication, the patient was clinically assessed by both a 
neuro surgeon and a psychiatrist to identify physical or psy-
chological adverse events. All patients were fully awake and 
responsive throughout the procedure, after which they were 
monitored for approximately 24 h as inpatients. The number, 
temperature and total duration of the sonications and the 
skull density ratio of the patients are listed in Appendix 1, 
Table S1. Brain MRI was evaluated immediately and at 
1 week, 1 month and 6 months after MRgFUS to detect the le-
sions and any other complications related to the sonications 
(Appendix 1, Figure S2).
Statistical analysis
We analyzed changes in clinical symptoms (Y-BOCS, CGI-S, 
CGI-I, HAM-D, HAM-A), neuropsychological function (K-
WAIS, Memory Quotient, COWAT, Stroop, Digit Span), 
global functioning (GAF) and body weight using linear 
mixed models for repeated measures, nonrestrictively assum-
ing an unstructured covariance matrix. A post hoc analysis 
with Bonferroni correction examined changes from baseline 
for each variable. Statistical analyses were performed using 
SPSS version 23.0 (SPSS Inc.). Statistical significance was set 
at p < 0.05 (2-tailed).
Results
Participants
Participant demographic and clinical characteristics are pre-
sented in Table 2.
Clinical outcomes 
Table 3 shows detailed preoperative and postoperative clini-
cal data for each patient. Mean Y-BOCS, HAM-D and HAM-
A scores decreased significantly across the 24-month follow-
up period (Y-BOCS, F6,10.0 = 18.6, p < 0.001; HAM-D, F6,10.0 = 
13.4, p < 0.001; HAM-A, F6,10.0 = 85.4, p < 0.001; Table 3 and 
Fig. 1A to C). Post hoc analyses indicated that obsessive– 
compulsive, depressive and anxiety symptoms began to sig-
nificantly improve as early as 1 week after MRgFUS 
(Y-BOCS, p = 0.035; HAM-D, p = 0.001; HAM-A, p = 0.002, af-
ter Bonferroni corrections) and the improvements continued 
throughout the 24-month follow-up period (all p < 0.05 after 
Bonferroni corrections). The Y-BOCS, HAM-D and HAM-A 
graphs for individual patients are presented in Appendix 1, 
Figure S3A to S3C. The mean CGI-S and CGI-I scores also de-
creased significantly over the 24-month follow-up period 
(CGI-S, F6,10.0 = 11.3, p = 0.001; CGI-I, F5,10.0 = 13.3, p < 0.001). 
For Y-BOCS, the mean ± standard deviation (SD) score of 
34.4 ± 2.3 at baseline decreased to 23.6 ± 4.5, 21.8 ± 4.8 and 
21.3 ± 6.2 at 6, 12 and 24 months, respectively. At 12 months, 
6 (54.5%) patients were responders and 3 (27.3%) patients 
were partial responders. At 24 months, 6 patients were re-
sponders, 2 (18.1%) were partial responders and 1 had 
achieved full remission. For HAM-D, the mean ± SD score of 
19.0 ± 5.3 at baseline decreased to 9.0 ± 3.5, 8.9 ± 5.4 and 7.6 ± 
5.3 at 6, 12 and 24 months, respectively. At 12 months, 6 pa-
tients were in remission and all were responders. At 
24 months, 7 (63.6%) patients were responders and 6 were in 
remission. For HAM-A, the mean ± SD score of 22.4 ± 5.9 at 
baseline decreased to 8.5 ± 4.6, 8.5 ± 4.9 and 7.9 ± 3.9 at 6, 12 
and 24 months, respectively. At 12 months, 8 (72.7%) patients 
were responders and 6 were in remission. At 24 months, 
8 patients were responders and 7 were in remission.
The mean GAF score increased significantly across the 
24-month follow-up period (F4,10.0 = 25.2, p < 0.001; Table 3 
and Fig. 1D). The mean GAF score showed significant im-
provement as early as 3 months after MRgFUS (the first 
 follow-up on GAF; p < 0.001 after Bonferroni correction). The 
GAF graphs for individual patients are presented in Appen-
dix 1, Figure S3D.
Neuropsychological function
Detailed neuropsychological function data for individual pa-
tients are shown in Table 4, Table 5 and Table 6. The mean 
Memory Quotient score improved significantly across the 
24-month follow-up period (F3,6.5 = 236.3, p < 0.001). We ob-
served no significant changes in K-WAIS, COWAT, Stroop or 
Digit Span scores.
Adverse events
All patients tolerated the MRgFUS procedure well. The 
most common adverse event during the procedure was 
headache. Seven patients (63.6%) had several short, periodic 
headaches during sonication at temperatures > 50°C. These 
symptoms were mild and resolved spontaneously or with a 
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single dose of analgesic medication. Five patients (45.5%) 
had increased vestibular symptoms, such as nausea, vomit-
ing or dizziness, which continued until the end of the proce-
dure. These symptoms resolved spontaneously or after a 
single dose of an antiemetic drug. Three patients (27.3%) 
felt increased anxiety, which subsided after a single benzo-
diazepine dose. Two patients (18.2%) complained of stom-
ach upset and were given a single dose of an H2 blocker. 
One patient (9.1%) experienced a transient warm sensation 
in the brain during sonication at higher temperatures. No 
significant physical adverse events (such as fatigue, urinary 
incontinence or seizure) or behavioural changes (such as hy-
pomania, personality changes, emotional blunting, indiffer-
ence or carelessness), which were reported in previous cap-
sulotomy studies,20,21 occurred during the 24-month 
follow-up period. We observed no significant changes in 
weight during the 24-month follow-up period (mean ± SD; 
66.3 ± 11.5 kg at baseline, 67.2 ± 11.7 kg at 6 months, 66.0 ± 
10.6 kg at 12 months, and 66.2 ± 11.8 kg at 24 months; F3,10.0 = 
0.3, p = 0.812). No significant psychiatric or behavioural 
Table 3: Individual clinical symptom measures after MRgFUS, 24-month follow-up (part 1 of 2)
Measure Pt. no. BL 1 wk 1 mo 3 mo 6 mo 12 mo 24 mo IR at 6 mo, % IR at 12 mo, % IR at 24 mo, %
Y-BOCS*
1 38 36 35 32 29 18 21 23.7 52.6 44.7
2 34 32 27 18 18 22 27 47.1 35.3 20.6
3 35 31 32 28 26 15 14 25.7 57.1 60.0
4 34 28 22 22 21 22 19 38.2 35.3 44.1
5 37 35 29 28 27 28 30 27.0 24.3 18.9
6 35 28 29 24 23 20 14 34.3 42.9 60.0
7 34 20 18 21 16 23 21 52.9 32.4 38.2
8 36 33 30 28 29 27 26 19.4 25.0 27.8
9 30 30 28 27 27 21 21 10.0 30.0 30.0
10 34 30 30 27 19 15 12 44.1 55.9 64.7
11 31 30 30 30 25 29 29 19.4 6.5 6.5
Mean ± SD
34.4 ± 
2.3
30.3 ± 
4.3
28.2 ± 
4.6
25.9 ± 
4.2
23.6 ± 
4.5
21.8 ± 
4.8
21.3 ± 
6.2
31.1 ± 13.3 36.1 ± 15.3 37.8 ± 18.9
HAM-D†
1 27 7 5 7 4 4 7 85.2 85.2 74.1
2 18 15 8 11 11 21 15 38.9 –16.7 16.7
3 25 11 13 12 11 6 3 56.0 76.0 88.0
4 20 10 6 10 9 6 5 55.0 70.0 75.0
5 24 10 5 9 15 14 15 37.5 41.7 37.5
6 19 11 10 11 9 5 2 52.6 73.7 89.5
7 17 9 5 10 11 13 14 35.3 23.5 17.6
8 13 10 8 6 8 10 1 38.5 23.1 92.3
9 16 8 10 11 9 3 9 43.8 81.3 43.8
10 9 6 9 6 2 6 3 77.8 33.3 66.7
11 21 13 12 16 10 10 10 52.4 52.4 52.4
Mean ± SD
19.0 ± 
5.3
10.0 
 ± 2.6
8.3 ± 
2.8
9.9 ± 
2.9
9.0 ± 
3.5
8.9 
 ± 5.4
7.6 
 ± 5.3
52.1 ± 16.4 49.4 ± 31.8 59.4 ± 27.7
HAM-A‡
1 34 5 6 6 4 4 7 88.2 88.2 79.4
2 17 14 7 7 7 19 15 58.8 –11.8 11.8
3 31 13 16 15 17 6 7 45.2 80.6 77.4
4 26 9 7 8 5 4 5 80.8 84.6 80.8
5 19 10 8 8 5 15 14 73.7 21.1 26.3
6 21 9 11 12 13 6 2 38.1 71.4 90.5
7 17 10 9 14 8 12 10 52.9 29.4 41.2
8 20 8 10 14 8 9 7 60.0 55.0 65.0
9 20 9 19 18 8 5 7 60.0 75.0 65.0
10 16 7 11 6 3 5 4 81.3 68.8 75.0
11 25 20 22 21 15 9 9 40.0 64.0 64.0
Mean ± SD
22.4 ± 
5.9
10.4 ± 
4.1
11.5 ± 
5.3
11.3 ± 
5.1
8.5 ± 
4.6
8.6 ± 
4.9
7.9 ± 
3.9
61.7 ± 17.3 56.9 ± 31.3 61.5 ± 24.7
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Table 3: Individual clinical symptom measures after MRgFUS, 24-month follow-up (part 2 of 2)
Measure Pt. no. BL 1 wk 1 mo 3 mo 6 mo 12 mo 24 mo IR at 6 mo, % IR at 12 mo, % IR at 24 mo, %
GAF§
1 30 — — 40 40 53 55 33.3 76.7 83.3
2 35 — — 45 45 36 42 28.6 2.9 20.0
3 30 — — 40 43 69 69 43.3 130.0 130.0
4 33 — — 43 51 55 55 54.6 66.7 66.7
5 32 — — 40 40 37 40 25.0 15.6 25.0
6 33 — — 45 45 60 65 36.4 81.8 97.0
7 42 — — 48 58 55 55 38.1 31.0 31.0
8 39 — — 43 43 48 50 10.3 23.1 28.2
9 43 — — 51 55 65 65 27.9 51.2 51.2
10 35 — — 47 60 65 70 71.4 85.7 100.0
11 42 — — 45 48 50 50 14.3 19.0 19.0
Mean ± SD
35.8 ± 
4.9
— —
44.3 ± 
3.6
48.0 ± 
7.1
53.9 ± 
10.8
56.0 ± 
10.3
34.8 ± 
17.4
53.1 ± 
38.8
59.2 ± 
38.6
CGI-S¶
1 7 7 7 5 5 4 4 — — —
2 6 6 5 4 4 4 5 — — —
3 6 6 6 5 4 3 3 — — —
4 6 5 4 4 4 4 4 — — —
5 7 7 6 5 5 5 5 — — —
6 6 5 5 4 4 4 3 — — —
7 7 5 4 4 4 4 4 — — —
8 6 6 6 5 5 4 4 — — —
9 5 5 5 4 4 4 4 — — —
10 6 5 6 4 4 3 2 — — —
11 5 5 5 5 5 5 5 — — —
Mean ± SD
6.1 ± 
0.2
5.6 ± 
0.2
5.4 ± 
0.3
4.5 ± 
0.2
4.4 ± 
0.2
4.0 ± 
0.2
3.9 ± 
0.3
— — —
CGI-I**
1 — 4 4 3 3 1 2 — — —
2 — 4 3 2 2 2 3 — — —
3 — 3 4 2 2 1 1 — — —
4 — 3 2 2 2 2 2 — — —
5 — 4 3 3 3 3 3 — — —
6 — 3 3 2 2 2 1 — — —
7 — 2 1 2 1 2 2 — — —
8 — 4 4 3 3 2 2 — — —
9 — 4 4 4 3 2 2 — — —
10 — 2 3 3 2 1 1 — — —
11 — 4 4 4 4 4 4 — — —
Mean ± SD —
3.4 ± 
0.2
3.2 ± 
0.3
2.7 ± 
0.2
2.5 ± 
0.2
2.0 ± 
0.3
2.1 ± 
0.3
— — —
BL = baseline; CGI-I = Clinical Global Impression–Improvement; CGI-S = Clinical Global Impression–Severity; GAF = Global Assessment of Functioning; HAM-A = Hamilton Rating Scale 
for Anxiety; HAM-D = Hamilton Rating Scale for Depression; IR = improvement rate; MRgFUS, magnetic resonance–guided focused ultrasound; SD = standard deviation; Y-BOCS = 
Yale–Brown Obsessive Compulsive Disorder Scale.
*Mean Y-BOCS scores decreased significantly across the 24-month follow-up period (linear mixed model; F6,10.0 = 18.6, p < 0.001).
†Mean HAM-D scores decreased significantly across the 24-month follow-up period (linear mixed model; F6,10.0 = 13.4, p < 0.001).
‡Mean HAM-A scores decreased significantly across the 24-month follow-up period (linear mixed model; F6,10.0 = 85.4, p < 0.001).
§Mean GAF scores increased significantly across the 24-month follow-up period (linear mixed model; F4,10.0 = 25.2, p < 0.001).
¶Mean CGI-S scores decreased significantly across the 24-month follow-up period (linear mixed model; F6,10.0 = 11.3, p = 0.001).
**Mean CGI-I scores decreased significantly across the 24-month follow-up period (linear mixed model; F5,10.0 = 13.3, p < 0.001).
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 adverse events, such as changes of personality, mania/ 
hypomania, impulsivity or alcohol consumption, were de-
clared by patients or caregivers or observed by psychiatrists 
(SJK and CHK) during the 2-year follow-up period.
Discussion
In this study of bilateral thermal lesioning of the ALIC using 
MRgFUS in patients with treatment-refractory OCD, we 
found significant improvement of obsessive–compulsive, de-
pressive and anxiety symptoms, with only a few transient 
and acceptable adverse events over 24 months of follow-up.
At 24 months, 54.6% of patients (6/11) were responders, 
18.1% (2/11) were partial responders and 9.1% (1/11) were in 
remission. Our findings are compatible with those of previ-
ous studies of capsulotomy in people with OCD, which 
showed a full response in approximately 50% (25% to 80%) of 
patients and a partial response in approximately 20% (0% to 
33%).14,22–24 A recent systemic review of observational studies 
of capsulotomy for OCD reported that after 12-month follow-
up, the mean reduction in Y-BOCS score and full response 
rate were 37% and 41%, respectively.21 A meta-analysis of 
deep brain stimulation including 31 studies that involved 
116 participants and targeted the striatal area (ALIC, ventral 
capsule, ventral striatum, nucleus accumbens and ventral 
caudate), subthalamic nucleus or inferior thalamic peduncle 
reported a global reduction of 45.1% in Y-BOCS score and a 
global responder percentage of 60.0%.25 The results of our 
study on obsessive–compulsive symptoms confirm that bilat-
eral thermal lesioning of the ALIC with MRgFUS appears to 
have an efficacy comparable to that reported in other capsu-
lotomy, cingulotomy or deep brain stimulation studies.
Of the 7 patients (including 3 partial responders) who did 
not show a full response at 6 months, 3 improved further and 
qualified as full responders at 12 and 24 months. These re-
sults imply that 6 months may not be long enough to draw 
Fig. 1: Improvement in clinical outcomes and global functioning. Data appear as mean ± standard error. Panels show the changes in mean 
(A) Y-BOCS, (B) HAM-D, (C) HAM-A and (D) GAF scores during the 24-month follow-up period after MRgFUS. Higher scores on Y-BOCS, 
HAM-D and HAM-A indicate more severe symptoms. Higher scores on GAF indicate better global psychosocial and occupational functioning. 
GAF = Global Assessment of Functioning; HAM-A = Hamilton Rating Scale for Anxiety; HAM-D = Hamilton Rating Scale for Depression; 
 MRgFUS = magnetic resonance–guided focused ultrasound; Y-BOCS = Yale–Brown Obsessive Compulsive Scale.
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conclusions about the effects of MRgFUS. Although still spec-
ulative, it may be necessary to inform the patients and care-
givers about this potential lag in response before surgery.
In terms of time course and efficacy, we found that 
 obsessive–compulsive symptoms began to significantly im-
prove as early as 1 week after MRgFUS and continued to im-
prove after 6 months. Some studies also found early onset of 
improvement (2 weeks to 3 months)14,22,23 and a delay in im-
provement (after 12 months) after capsulotomy22,24 or cingu-
lotomy.26,27 Taken together, the previous and current findings 
suggest that the therapeutic effects of neurosurgical interven-
tions are related to functional brain interruption and reorg-
anization after lesioning.22,27
Moreover, we observed significant improvement in de-
pressive and anxiety symptoms after MRgFUS. The rates of 
improvement of depression and anxiety in this study were in 
line with those reported by previous studies (44.7% to 68.1% 
for HAM-D and 48.4% to 77.0% for HAM-A).28–30 Interest-
ingly, we observed significant improvements in depression 
and anxiety symptoms as early as 1 week after MRgFUS. An-
other recent study reported a significant reduction in HAM-
D and HAM-A scores as early as 2 weeks after bilateral cap-
sulotomy.14 A study using deep brain stimulation of the 
nucleus accumbens for refractory OCD also reported signifi-
cant decreases in HAM-D and HAM-A scores, and the effects 
of deep brain stimulation on anxiety and depression were 
Table 5: COWAT after MRgFUS, 24-month follow-up
Pt. no.
COWAT
Semantic Phonemic
BL 6 mo 12 mo 24 mo BL 6 mo 12 mo 24 mo
1 28 20 25 24 61 58 57 49
2 21 16 — 16 47 41 — 33
3 15 21 20 18 30 28 35 46
4 13 14 — 14 24 21 — 31
5 24 20 — 21 40 46 — 39
6 17 19 17 22 39 27 35 38
7 19 14 16 16 19 21 32 34
8 11 12 9 14 23 38 31 29
9 18 13 16 12 27 30 35 28
10 16 19 14 17 21 21 34 39
11 32 33 30 — 59 89 70 —
Mean ± SD* 19.5 ± 6.4 18.3 ± 5.8 18.3 ± 6.6 17.4 ± 3.9 35.5 ± 15.0 38.2 ± 20.6 41.1 ± 14.3 36.6 ± 7.0
BL = baseline; COWAT = Controlled Oral Word Association Test; MRgFUS = magnetic resonance–guided focused ultrasound; pt. = patient; SD = standard deviation.
*Mean values at 12 months were from 8 patients (data for patients 2, 4 and 5 were missing). Mean values at 24 months were from 10 patients (data for patient 11 were 
missing). 
Table 4: K-WAIS and Memory Quotient tests after MRgFUS, 24-month follow-up
Pt. no.
K-WAIS Memory Quotient (Rey-Kim Memory Test)*
BL 6 mo 12 mo 24 mo BL 6 mo 12 mo 24 mo
1 118 124 130 124 106 119 121 127
2 115 119 — 98 99 111 — 98
3 80 80 89 92 94 97 115 117
4 78 81 — 88 100 97 — 98
5 107 110 — 107 100 107 — 116
6 98 90 101 105 89 93 99 114
7 71 74 73 83 59 75 92 81
8 59 71 72 75 84 109 104 102
9 92 99 96 96 110 122 134 125
10 77 71 86 87 103 109 116 123
11 105 109 120 — 91 97 101 —
Mean ± SD† 90.9 ± 19.3 93.5 ± 19.7 95.9 ± 20.7 95.5 ± 14.0 94.1 ± 13.9 103.3 ± 13.3 110.3 ± 13.7 110.1 ± 14.8
BL = baseline; K-WAIS = Wechsler Adult Intelligence Scale, Korean version; MRgFUS = magnetic resonance–guided focused ultrasound; pt. = patient; SD = standard deviation.
*Mean Memory Quotient scores increased significantly across the 24-month follow-up period (linear mixed model; F3,6.5 = 236.3, p < 0.001).
†Mean values at 12 months were from 8 patients (data for patients 2, 4 and 5 were missing). Mean values at 24 months were from 10 patients (data for patient 11 were 
missing). 
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more robust and immediate than those on obsessive– 
compulsive symptoms,31 consistent with our results. These 
findings suggest the possibility of using neurosurgical proced-
ures such as MRgFUS or deep brain stimulation to treat  major 
depressive or anxiety disorders in addition to OCD. The im-
provement in obsessive–compulsive, depressive and anxiety 
symptoms noted within a week of the procedures could have 
been placebo effects rather than true therapeutic effects. How-
ever, this is less likely because the improvements continued 
throughout the 24-month follow-up period, and OCD is 
known to be associated with a reduced placebo response.32
One of the most fascinating results of this study was the 
lack of major adverse events. Only mild and transient com-
plications, such as headache, vestibular symptoms, anxiety 
and a hot sensation in the brain, were reported, and all of 
these resolved immediately after the procedure.
More importantly, overall neuropsychological function 
was unchanged or improved over time. Memory Quotient 
scores significantly improved, and K-WAIS, COWAT, Stroop 
and Digit Span scores were unchanged. Similar to our results, 
other studies have reported improved visuospatial mem-
ory.33 Our results suggest that bilateral thermal lesioning of 
the ALIC with MRgFUS does not negatively affect various 
domains of neuropsychological function, including intelli-
gence, memory, attention, learning ability and executive 
function. The positive effect on memory function may be ex-
plained by several mechanisms, such as amelioration of 
symptoms or interruption of abnormal circuits.33 However, 
improvements in Memory Quotient should be interpreted 
with caution, because they could have been due to learning 
effects through repeated examinations.
To date, most stereotactic ALIC ablative procedures have 
been performed using radiofrequency thermal ablation or 
gamma knife. Because of the nature of the radiofrequency 
 ablation technique, lesion size can be quite variable and can 
injure adjacent areas, resulting in substantial risk of com-
plications.20 Gamma knife is a noninvasive technique and ap-
pears to have fewer risks, but still has serious adverse effects, 
including radiation-induced complications.3
Rates of transient adverse outcomes of capsulotomy, in-
cluding asymptomatic hemorrhage, seizure and hallucina-
tions via radiofrequency thermal ablation and gamma knife, 
have been reported to be 0% to 220% and 0% to 260% across 
studies, respectively.21 Rates of serious or permanent adverse 
outcomes, including intracranial hemorrhage, brain edema 
with permanent sequela, hemiparesis, personality change, 
cognitive impairment, weight gain, recurrent seizures and 
more, have been reported to be 11.2% to 40% and 0% to 40%, 
respectively.21 It is difficult to compare these rates of adverse 
events, especially transient ones, because criteria varied across 
studies, and the studies had relatively small sample sizes. 
However, in our study, we found no serious or permanent 
 sequelae, suggesting more favourable outcomes with respect 
to adverse events. Although a recent randomized trial of cap-
sulotomy in refractory OCD with gamma knife suggested that 
smaller lesions would be expected to come with fewer serious 
adverse events, development of delayed brain cyst and manic 
episodes were reported in that study.24
Currently, deep brain stimulation is considered an alterna-
tive to stereotactic ablation neurosurgery for OCD.3,31 It has the 
advantages of adjustability, less destructiveness and reversibil-
ity. However, it is also an invasive procedure with the place-
ment of leads in the brain, which can increase vulnerability to 
hemorrhage or infection. It also comes with a risk of device 
failure and requires repeated surgery to exchange the battery.
Bilateral thermal lesioning of the ALIC with MRgFUS has 
obvious advantages over conventional neurosurgical proced-
ures. It is an incisionless, nonradiation ablation method. The 
ablation temperature and the lesion size and location can be 
verified in real time with magnetic resonance thermography 
and sequential magnetic resonance images, enabling neuro-
surgeons to make adjustments and reposition immediately in 
case of need.34 Thermal lesions created by MRgFUS are pre-
cise and can be confined to the ALIC without extensive tissue 
Table 6: Stroop and Digit Span tests after MRgFUS, 24-month follow-up
Pt. no
Stroop* Digit Span (forward)
BL 6 mo 12 mo 24 mo BL 6 mo 12 mo 24 mo
1 0.70 0.79 0.75 0.75 8 13 10 10
2 1.45 1.44 — 1.75 14 13 — 14
3 1.46 1.40 1.17 0.95 9 10 14 10
4 1.42 1.01 — 1.13 9 10 — 14
5 0.98 1.07 — 1.11 12 13 — 13
6 1.53 2.08 2.04 1.10 12 11 14 14
7 1.56 1.59 1.53 1.47 13 10 11 11
8 1.25 1.16 1.16 1.13 9 7 7 11
9 0.96 0.89 1.02 1.01 7 6 12 8
10 1.57 2.11 1.45 1.23 8 7 8 9
11 0.84 0.74 0.68 — 11 11 14 —
Mean ± SD† 1.25 ± 0.32 1.30 ± 0.48 1.22 ± 0.45 1.16 ± 0.28 10.2 ± 2.3 10.1 ± 2.5 11.3 ± 2.8 11.4 ± 2.2
BL = baseline; pt. = patient; MRgFUS = magnetic resonance–guided focused ultrasound; SD = standard deviation; Stroop = Colour Word Stroop Test, Korean version.
*Mean reaction time for correct trials (s). 
†Mean values at 12 months were from 8 patients (data for patients 2, 4 and 5 were missing). Mean values at 24 months were from 10 patients (data for patient 11 were missing). 
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damage beyond the target, minimizing complications with-
out losing efficacy.20 In the present study, no serious peri-
lesional edemas were found.
Limitations
Several limitations in this study should be addressed. First, 
this study was an open-label design, and assessments were 
not performed by independent, blinded raters. This may 
have resulted in a bias in favour of improved symptoms for 
both the patients and the raters. In addition, open, uncon-
trolled psychosurgery studies tend to show inflated effect 
sizes. Lopes and colleagues35 reported a response rate of 60% 
(3/5) after 48 months following gamma capsulotomy in their 
open, uncontrolled pilot study,but in their subsequent 
 double-blind, placebo-controlled, randomized clinical trial, 
the response rate was 25% at 12 months.24 Therefore, ran-
domized controlled trials should follow this study to vali-
date the effects of MRgFUS on OCD. 
Second, we did not use systematic assessment tools to evalu-
ate psychiatric adverse events, such as mood instability or per-
sonality changes, which have been reported in previous deep 
brain stimulation or ablative intervention studies.20,21 Although 
the patients were evaluated by experienced psychiatrists using 
mental status examinations and unstructured psychiatric inter-
views at each visit, we cannot rule out the possibility that sub-
tle psychiatric adverse effects were overlooked. Further studies 
using formal systematic assessments of psychiatric or behav-
ioural changes, such as personality, mania/hypomania, impul-
sivity, alcohol consumption and more, are warranted. 
Third, neuropsychological evaluations were conducted using 
the same versions in each assessment. It is possible that learn-
ing effects could have affected the results, although the inter-
vals between the assessments were not short (6 or 12 months). 
Fourth, no patients received regular formal cognitive be-
havioural therapy sessions after surgery, although they were 
encouraged at each follow-up visit to continue with the ERP 
they learned before surgery. Patients 1, 3, 6, 9 and 10 prac-
tised ERP continuously after surgery and were able to stand 
the procedure much better than before. In turn, their obses-
sions and especially compulsions decreased further. Patients 
4, 7 and 8 practised ERP irregularly, but also were able to 
stand the procedure better than before. Patients 2, 5 and 11 
could not stand ERP and seldom practised it. 
Fifth, no patients in this study had used higher doses of 
clomipramine, because they had used it as an augmentation 
to selective serotonin reuptake inhibitors. Although we en-
sured that all participants were treatment-refractory, because 
they did not respond to more than 2 selective serotonin reup-
take inhibitors at maximum tolerable doses and a submaxi-
mal dose of clomipramine, we could not rule out the possibil-
ity of some patients responding to a higher maximal dose of 
clomipramine. 
Finally, functional neuroimaging studies, such as PET or 
fMRI, to elucidate underlying neural mechanisms for the ef-
fects of MRgFUS on obsessive–compulsive, depressive and 
anxiety symptoms were not included in this study. Further 
studies using functional neuroimaging are needed.
Conclusion
The results of this study indicate that bilateral thermal lesion-
ing of the ALIC with MRgFUS may be an effective and safe 
approach for improving obsessive–compulsive, depressive 
and anxiety symptoms in patients with treatment-refractory 
OCD. The side effects of MRgFUS capsulotomy seem to be 
mild and transient. In addition, it may not negatively affect 
neuropsychological function. However, the small sample size 
and 2-year follow-up period of this study were not enough, 
especially to detect adverse events. Larger randomized con-
trolled trials with sham controls and long-term follow-up are 
needed to validate these promising results.
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